Method for producing polypeptide hetero-oligomer

Patent metadata

Field	Value
Publication number	US-11142587-B2
Application number	US-201615562186-A
Country	US
Kind code	B2
Filing date	Mar 31, 2016
Priority date	Apr 1, 2015
Publication date	Oct 12, 2021
Grant date	Oct 12, 2021

Abstract

It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating homo variants of plural types of heavy chain constant region-containing polypeptides differing in antigen-binding activity under a reducing condition that reorganize the inter-polypeptide disulfide bond between cysteine residues outside of core hinge regions. A feature of the production method of the present invention is that amino acid residues in the core hinge regions do not form any disulfide bond.

First claim

The invention claimed is:

1. A method for producing a heteromultimer, the method comprising:
(a) providing a first molecule comprising two copies of a first antibody heavy chain and two copies of a first antibody light chain,
wherein the first antibody heavy chain comprises a heavy chain constant region of human IgG1 type that has no core hinge region Cys residues and does not have a Cys at position 220 (EU numbering),
wherein the first antibody light chain comprises a light chain constant region comprising one or more Cys residues, including a Cys at position 214 (EU numbering),
wherein the first molecule has a first antigen-binding activity, and
wherein the two copies of the first antibody light chain are linked to each other by a Cys-Cys disulfide bond linking their respective positions 214 (EU numbering);
(b) providing a second molecule comprising two copies of a second antibody heavy chain different from the first antibody heavy chain and two copies of a second antibody light chain different from the first antibody light chain,
wherein the second antibody heavy chain comprises a heavy chain constant region of human IgG1 type that has no core hinge region Cys residues and does not have a Cys at position 220 (EU numbering),
wherein the second antibody light chain comprises a light chain constant region comprising one or more Cys residues including a Cys at position 214 (EU numbering),
wherein the second molecule has a second antigen-binding activity different from the first antigen-binding activity, and
wherein the two copies of the second antibody light chain are linked to each other by a Cys-Cys disulfide bond linking their respective positions 214 (EU numbering);
(c) incubating the first and second molecules together under a reducing condition that allows Cys-Cys disulfide bonds in the first molecule and second molecule to isomerize; and
(d) obtaining a heteromultimer comprising a first arm comprising the first antibody heavy and light chains associated together and a second arm comprising the second antibody heavy and light chains associated together,
wherein the only covalent bond linking the first and second arms together is a Cys-Cys disulfide bond linking position 214 (EU numbering) of the first antibody light chain and position 214 (EU numbering) of the second antibody light chain.

2. The method of claim 1 , wherein the first and second antibody heavy chains both meet the criteria of one of the following (1) to (3) (all position numbers according to EU numbering):
(1) an amino acid residue other than Cys at position 220, an amino acid residue other than Cys at position 226, and an amino acid residue other than Cys at position 229; or
(2) a deletion of all of positions 219 to 229; or
(3) the sequence Tyr-Gly-Pro-Pro at positions 220 to 225, an amino acid residue other than Cys at position 226, and an amino acid residue other than Cys at position 229.

3. The method of claim 1 , wherein the heavy chain constant regions of the first and second antibody heavy chains each comprise a CH3 region, and one or more of (A) to (F) is true:
(A) amino acid residues at positions 356 and 439 (EU numbering) in the CH3 region of the first antibody heavy chain have the same type of charge (+ or −),
(B) amino acid residues at positions 357 and 370 (EU numbering) in the CH3 region of the first antibody heavy chain have the same type of charge (+ or −),
(C) amino acid residues at positions 399 and 409 (EU numbering) in the CH3 region of the first antibody heavy chain have the same type of charge (+ or −),
(D) amino acid residues at positions 356 and 439 (EU numbering) in the CH3 region of the second antibody heavy chain have the same type of charge (+ or −),
(E) amino acid residues at positions 357 and 370 (EU numbering) in the CH3 region of the second antibody heavy chain have the same type of charge (+ or −),
(F) amino acid residues at positions 399 and 409 (EU numbering) in the CH3 region of the second antibody heavy chain have the same type of charge (+ or −),
provided that,
when both (A) and (D) are true, the type of charge in (A) is the opposite of the type of charge in (D), and
when both (B) and (E) are true, the type of charge in (B) is the opposite of the type of charge in (E), and
when both (C) and (F) are true, the type of charge in (C) is the opposite of the type of charge in (F).

4. The method of claim 3 , wherein the amino acid residues at positions 356, 399, 409, and 439 (EU numbering) of the first antibody heavy chain are all positively charged, and the amino acid residues at positions 356, 399, 409, and 439 (EU numbering) of the second antibody heavy chain are all negatively charged.

5. The method of claim 1 , wherein the first molecule has no disulfide bonds between the first antibody heavy chains and the second molecule has no disulfide bonds between the second antibody heavy chains.

6. The method of claim 1 , wherein the heteromultimer is a bispecific antibody.

7. A method for producing a heteromultimer, the method comprising:
(a) providing a first molecule comprising two copies of a first antibody heavy chain and two copies of a first antibody light chain,
wherein the first antibody heavy chain comprises a heavy chain constant region of human IgG4 type that has no core hinge region Cys residues and does not have a Cys at position 131 (EU numbering),
wherein the first antibody light chain comprises a light chain constant region comprising one or more Cys residues, including a Cys at position 214 (EU numbering),
wherein the first molecule has a first antigen-binding activity, and
wherein the two copies of the first antibody light chain are linked to each other by a Cys-Cys disulfide bond linking their respective positions 214 (EU numbering);
(b) providing a second molecule comprising two copies of a second antibody heavy chain different from the first antibody heavy chain and two copies of a second antibody light chain different from the first antibody light chain,
wherein the second antibody heavy chain comprises a heavy chain constant region of human IgG4 type that has no core hinge region Cys residues and does not have a Cys at position 131 (EU numbering),
wherein the second antibody light chain comprises a light chain constant region comprising one or more Cys residues including a Cys at positions 214 (EU numbering),
wherein the second molecule has a second antigen-binding activity different from the first antigen-binding activity, and
wherein the two copies of the second antibody light chain are linked to each other by a Cys-Cys disulfide bond linking their respective positions 214 (EU numbering);
(c) incubating the first and second molecules together under a reducing condition that allows Cys-Cys disulfide bonds in the first molecule and second molecule to isomerize; and
(d) obtaining a heteromultimer comprising a first arm comprising the first antibody heavy and light chains associated together and a second arm comprising the second antibody heavy and light chains associated together,
wherein the only covalent bond linking the first and second arms together is a Cys-Cys disulfide bond linking position 214 (EU numbering) of the first antibody light chain and position 214 (EU numbering) of the second antibody light chain.

8. The method of claim 7 , wherein the first and second antibody heavy chains both meet the criteria of one of the following (1) to (3) (all position numbers according to EU numbering):
(1) an amino acid residue other than Cys at position 131, an amino acid residue other than Cys at position 226, and an amino acid residue other than Cys at position 229; or
(2) an amino acid residue other than Cys at position 131, an amino acid residue other than Cys at position 226, a Pro at po

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Igawa Tomoyuki
• Katada Hitoshi
• Hori Yuji
• Kadono Shojiro

Classifications

• G01N33/50 Primary

  Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q) · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C07K16/00

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K2317/53

  Hinge · CPC title